Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890134331> ?p ?o ?g. }
Showing items 1 to 82 of
82
with 100 items per page.
- W2890134331 abstract "4519 Background: Tandem HDC with carbo/etoposide (CE) is curative for a portion of relapsed GCT pts. However, outcomes of refractory or high-risk relapsed pts remain poor. We tested a new HDC regimen of GemDMC, based on DNA damage repair inhibition. We combined BEV with HDC given their potential synergy and the high vascularity of GCT metastases. Methods: Eligibility: Intermediate (int)/high-risk (Beyer Model), creatinine ≤1.8 mg/dL and adequate organ function. HDC included BEV (5 mg/kg) preceding GemDMC (HDC #1) and ifosfamide/CE (ICE) (HDC #2). Following accrual of 42 pts, we amended the trial omitting BEV. The trial was powered to distinguish a target 50% 2-yr RFS from an expected 25% in this population. Results: We enrolled 69 male pts in cohorts 1 (BEV, N=42) and 2 (no BEV, N=27) (Table). Pts were heavily pretreated and most had refractory tumors. Main AE: mucositis and renal (4 HDC-related deaths in cohort 1, 1 in cohort 2). Tumor markers normalized in 90% pts with active tumors at HDC. After HDC, 19 pts were in CR and 28 in PRm- (of these, 22 had residual lesions resected with no viable tumor found in 20/22, 2 xRT, 4 monitored). Median f/u = 39 (2-105) mo. The 2-yr RFS rates in cohorts 1 and 2 = 52% and 78%, respectively. Their respective 2-yr OS rates = 55% and 81%. Conclusions: Sequential HDC with GemDMC–ICE shows encouraging outcomes in heavily pretreated and refractory GCT, exceeding the anticipated results. Addition of BEV increases toxicity but not tumor control. Clinical trial information: NCT00936936. [Table: see text]" @default.
- W2890134331 created "2018-09-27" @default.
- W2890134331 creator A5004417292 @default.
- W2890134331 creator A5008861348 @default.
- W2890134331 creator A5009162219 @default.
- W2890134331 creator A5010129367 @default.
- W2890134331 creator A5017847251 @default.
- W2890134331 creator A5023203245 @default.
- W2890134331 creator A5029237145 @default.
- W2890134331 creator A5039986529 @default.
- W2890134331 creator A5048913229 @default.
- W2890134331 creator A5051786644 @default.
- W2890134331 creator A5055885925 @default.
- W2890134331 creator A5058115259 @default.
- W2890134331 creator A5071526808 @default.
- W2890134331 creator A5080526034 @default.
- W2890134331 creator A5082402405 @default.
- W2890134331 date "2017-05-20" @default.
- W2890134331 modified "2023-09-22" @default.
- W2890134331 title "Infusional gemcitabine + docetaxel/melphalan/carboplatin (GemDMC) ± bevacizumab (BEV) as an effective high-dose chemotherapy (HDC) regimen for refractory of poor-risk relapsed germ-cell tumors (GCT)." @default.
- W2890134331 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.4519" @default.
- W2890134331 hasPublicationYear "2017" @default.
- W2890134331 type Work @default.
- W2890134331 sameAs 2890134331 @default.
- W2890134331 citedByCount "2" @default.
- W2890134331 countsByYear W28901343312019 @default.
- W2890134331 countsByYear W28901343312020 @default.
- W2890134331 crossrefType "journal-article" @default.
- W2890134331 hasAuthorship W2890134331A5004417292 @default.
- W2890134331 hasAuthorship W2890134331A5008861348 @default.
- W2890134331 hasAuthorship W2890134331A5009162219 @default.
- W2890134331 hasAuthorship W2890134331A5010129367 @default.
- W2890134331 hasAuthorship W2890134331A5017847251 @default.
- W2890134331 hasAuthorship W2890134331A5023203245 @default.
- W2890134331 hasAuthorship W2890134331A5029237145 @default.
- W2890134331 hasAuthorship W2890134331A5039986529 @default.
- W2890134331 hasAuthorship W2890134331A5048913229 @default.
- W2890134331 hasAuthorship W2890134331A5051786644 @default.
- W2890134331 hasAuthorship W2890134331A5055885925 @default.
- W2890134331 hasAuthorship W2890134331A5058115259 @default.
- W2890134331 hasAuthorship W2890134331A5071526808 @default.
- W2890134331 hasAuthorship W2890134331A5080526034 @default.
- W2890134331 hasAuthorship W2890134331A5082402405 @default.
- W2890134331 hasConcept C121332964 @default.
- W2890134331 hasConcept C126322002 @default.
- W2890134331 hasConcept C142424586 @default.
- W2890134331 hasConcept C143998085 @default.
- W2890134331 hasConcept C2776694085 @default.
- W2890134331 hasConcept C2776938808 @default.
- W2890134331 hasConcept C2777802072 @default.
- W2890134331 hasConcept C2778119113 @default.
- W2890134331 hasConcept C2778239845 @default.
- W2890134331 hasConcept C2778684742 @default.
- W2890134331 hasConcept C2780258809 @default.
- W2890134331 hasConcept C2781190966 @default.
- W2890134331 hasConcept C2781413609 @default.
- W2890134331 hasConcept C2781451048 @default.
- W2890134331 hasConcept C71924100 @default.
- W2890134331 hasConcept C87355193 @default.
- W2890134331 hasConceptScore W2890134331C121332964 @default.
- W2890134331 hasConceptScore W2890134331C126322002 @default.
- W2890134331 hasConceptScore W2890134331C142424586 @default.
- W2890134331 hasConceptScore W2890134331C143998085 @default.
- W2890134331 hasConceptScore W2890134331C2776694085 @default.
- W2890134331 hasConceptScore W2890134331C2776938808 @default.
- W2890134331 hasConceptScore W2890134331C2777802072 @default.
- W2890134331 hasConceptScore W2890134331C2778119113 @default.
- W2890134331 hasConceptScore W2890134331C2778239845 @default.
- W2890134331 hasConceptScore W2890134331C2778684742 @default.
- W2890134331 hasConceptScore W2890134331C2780258809 @default.
- W2890134331 hasConceptScore W2890134331C2781190966 @default.
- W2890134331 hasConceptScore W2890134331C2781413609 @default.
- W2890134331 hasConceptScore W2890134331C2781451048 @default.
- W2890134331 hasConceptScore W2890134331C71924100 @default.
- W2890134331 hasConceptScore W2890134331C87355193 @default.
- W2890134331 hasLocation W28901343311 @default.
- W2890134331 hasOpenAccess W2890134331 @default.
- W2890134331 hasPrimaryLocation W28901343311 @default.
- W2890134331 isParatext "false" @default.
- W2890134331 isRetracted "false" @default.
- W2890134331 magId "2890134331" @default.
- W2890134331 workType "article" @default.